Oncology
Latest news
826 articles · 20 / page
Cancer Statistics in the United States, 2026: Trends, Disparities, and Future Challenges
In 2026, approximately 2.1 million new cancer cases and 626,140 deaths are projected in the U.S. Advances in prevention, early detection, and treatment have increased survival rates and averted millions of deaths, yet disparities and rising
Retifanlimab Plus Chemotherapy Significantly Extends Overall Survival in First-Line Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial
Executive Highlights The POD1UM-304 phase 3 trial marks a significant milestone in the management of...
Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC
The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m
Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer
Researchers have discovered that Zhenqi Fuzheng Granule enhances PD-1 antibody efficacy in colorectal cancer by modulating the gut microbiota-SCFA-GPR109A axis, effectively suppressing tumor glycolysis and reversing immune exhaustion within
Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer
Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l
Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia
A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term tre
Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer
Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib’s therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for personalized
Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL
The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, high
Dual Inhibition of VEGF and EGFR: A New Precision Paradigm for Krebs Cycle-Mutated Solid Tumors
The Phase II BRISK trial demonstrates that the combination of bevacizumab and erlotinib provides significant clinical activity in patients with solid tumors harboring Krebs cycle gene mutations, particularly in FH-deficient renal cell carci
HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability
A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s
Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino
T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08
The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat
Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights
This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise
Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer
Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str
SARC031 Trial: Why Combined MEK and mTOR Inhibition Failed to Translate from Mice to Men in MPNST
The SARC031 Phase 2 trial evaluated selumetinib and sirolimus for advanced MPNST. Despite strong preclinical rationale, the combination showed minimal clinical benefit, though correlative studies on cfDNA and PET imaging offer vital insight
Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial
The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profil
Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial
A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.
Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl
Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial
The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.
Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer
This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary tre
Browse by specialty
Open language-specific specialty feeds and department pages.